Thu, Mar. 19, 11:31 AM
Wed, Mar. 18, 4:12 PM
Jul. 14, 2014, 9:12 AM
- Ventrus Biosciences (NASDAQ:VTUS) shareholders approve the issuance of common stock for the merger with Assembly Pharmaceuticals. The transaction was effective at 5 pm on July 11, 2014. Ventrus shareholders also approved a 1-for-5 reverse stock split and the change of corporate name to Assembly Biosciences. It will begin trading under the symbol "ASMB" today.
Jun. 16, 2014, 12:45 PM
Jun. 5, 2014, 12:49 PM
Jun. 5, 2014, 12:01 PM
- Shares of pico cap Ventrus Biosciences (VTUS +19.5%) jump on 3x higher volume. Today's action follows a breakout on May 29 when prices popped 23% on 14-fold surge in volume.
- Traders appear to be taking positions before the company's pre-IND meeting with the FDA on June 19 where the parties will discuss guidance regarding an approval path for Dolizem (diltiazem hydrochloride cream) as a treatment for anal fissures. Based on a positive outcome of the meeting, Ventrus plans to file an NDA in 2H 2014 with an expected PDUFA date about a year later.
- On February 12, shares cratered 61% on turnover of 18M shares after the firm reported that Dolizem failed to outperform placebo in a second Phase 3 trial. In the first Phase 3, the product did demonstrate a statistically significant improvement in pain versus placebo.
- The company's previously-announced merger with Assembly Pharmaceuticals will close around July 10. The name of the combined firm will be Assembly Biosciences trading under the ticker "ASMB."
May 29, 2014, 12:47 PM
May 19, 2014, 12:45 PM
May 19, 2014, 8:40 AM
- Ventrus Biosciences (VTUS) merges with its wholly-owned subsidiary Assembly Acquisition (merger sub) and Assembly Pharmaceuticals. After the transaction, Assembly Acquisition will cease and Assembly Pharmaceuticals will survive as a wholly-owned subsidiary of Ventrus. Share of Assembly will be automatically converted into Ventrus shares at a specific exchange ratio (undisclosed).
Feb. 12, 2014, 9:54 AM
- Ventrus Biosciences' (VTUS) shares collapse 61% after its Diltiazem Cream for patients with anal fissures failed to lower pain more than a placebo in a Phase III trial.
- Diltiazem is designed to reduce pain associated with or following defecation by dilating the blood vessels that supply the associated region. (Previous)
Feb. 12, 2014, 9:10 AM
Feb. 12, 2014, 8:26 AM
- Ventrus Biosciences' (VTUS) Diltiazem Cream to treat patients with anal fissures improved their symptoms in a second Phase III trial, as expected.
- However, the placebo effect in the control group was greater than anticipated, resulting in no significant difference between the treatments.
- In the first pivotal Phase 3 trial, Diltiazem did perform better than the placebo.
- Ventrus plans to request a pre-NDA meeting with the FDA to determine its next steps. (PR)
Sep. 13, 2013, 9:12 AM
Sep. 11, 2013, 12:45 PM
Sep. 11, 2013, 9:10 AM
Sep. 11, 2013, 8:49 AM
- Ventrus Biosciences (VTUS) says two clinical dermal safety studies of VEN 307 demonstrate the treatment is safe and well tolerated.
- No serious AE's were reported.
- All pharmacokinetic parameters were met in a separate study, consistent with an earlier investigator sponsored trial.
- The data "mark another important step in [the] effort to develop and commercialize [the drug]," CEO Russell Ellison says.
- VEN 307 is currently in a second pivotal Phase 3 trial. (PR)
- Shares +12% premarket.
ASMB vs. ETF Alternatives
Other News & PR